SIRT6-activating drug reduces osteoarthritis severity in aging mice
In old mice, weekly injections of MDL-800 for 6 months reduced cartilage damage, bone overgrowth, and other signs of osteoarthritis compared to control mice. The drug appeared to reduce DNA damage and activate repair pathways in joint cells.
Why it matters: Osteoarthritis is a common aging-related disease; understanding how to slow joint damage could improve quality of life in older people.
Keep in mind: This study was conducted in mice only; whether MDL-800 works similarly in humans or would be safe as a treatment remains unknown.
AI-assisted explanation based on the supplied abstract. Read the linked source for full context.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Sep 22, 2026 · Discovered: Sep 22, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Animal
- Sample size
- —
- Duration
- 6 months
- Population
- Male 18-month-old mice
- Primary outcome
- Severity of age-associated osteoarthritis (OA) at 24 months, assessed by histology, micro-CT, and histomorphometry
- Effect size
- —
- Significance
- Significant
- Journal
- Arthritis & rheumatology (Hoboken, N.J.)
- Published
- Sep 22, 2026
Sources
Primary source
- Arthritis & rheumatology (Hoboken, N.J.) ↗Peer reviewed
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.